The importance of choosing the right strategy to treat small cell carcinoma of the cervix: a comparative analysis of treatments

• Published in: BMC cancer Vol. 21; no. 1; pp. 1 - 1046
• Main Authors: Kawamura, Mariko, Koide, Yutaro, Murai, Taro, Ishihara, Shunichi, Takase, Yuuki, Murao, Takayuki, Okazaki, Dai, Yamaguchi, Takahiro, Uchiyama, Kaoru, Itoh, Yoshiyuki, Kodaira, Takeshi, Shibamoto, Yuta, Mizuno, Mika, Kikkawa, Fumitaka, Naganawa, Shinji
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 23.09.2021; BioMed Central; BMC
• Subjects: Cancer; Cancer therapies; Care and treatment; Cervical cancer; Cervix; Chemotherapy; Clinical outcomes; Comparative analysis; Development and progression; Gynecology; Lungs; Medical prognosis; Medical records; Metastasis; Multivariate analysis; Obstetrics; Oncology, Experimental; Patients; Radiation therapy; Rare cancer; Small cell carcinoma; Surgery; Tumors; Japan
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-021-08772-x

Background Standard treatments for small cell carcinoma of the cervix (SCCC) have not been established. In this study, we aimed to estimate the optimal treatment strategy for SCCC. Methods This was a multicenter retrospective study. Medical records of patients with pathologically proven SCCC treated between 2003 and 2016 were retrospectively analyzed. Overall survival (OS) was plotted using the Kaplan-Meier method. Log-rank tests and Cox regression analysis were used to assess the differences in survival according to stage, treatment strategy, and chemotherapy regimen. Results Data of 78 patients were collected, and after excluding patients without immunohistopathological staining, 65 patients were evaluated. The median age of the included patients was 47 (range: 24-83) years. The numbers of patients with International Federation of Gynecology and Obstetrics (FIGO) 2018 stages I-IIA, IIB-IVA, IVB were 23 (35%), 34 (52%), and 8 (12%), respectively. Of 53 patients who had undergone chemotherapy, 35 and 18 received SCCC and non-SCCC regimens as their first-line chemotherapy regimen, respectively. The 5-year OS for all patients was 49%, while for patients with FIGO stages I-IIA, IIB-IVA, IVB, it was 60, 50, and 0%, respectively. The 5-year OS rates for patients who underwent treatment with SCCC versus non-SCCC regimens were 59 and 13% (p < 0.01), respectively. This trend was pronounced in locally advanced stages. Multivariate analysis showed that FIGO IVB at initial diagnosis was a significant prognostic factor in all patients. Among the 53 patients who received chemotherapy, the SCCC regimen was associated with significantly better 5-year OS in both the uni- and multivariate analyses. Conclusion Our results suggest that the application of an SCCC regimen such as EP or IP as first-line chemotherapy for patients with locally advanced SCCC may play a key role in OS. These findings need to be validated in future nationwide, prospective clinical studies. Keywords: Small cell carcinoma, Cervical cancer, Rare cancer, Chemotherapy